Latest Debt Facilities News

Nexalis Therapeutics has locked in a $53 million non-dilutive funding facility with Point8 Capital, replacing its previous lender and supporting three clinical programs targeting breakthrough cancer pain, panic disorder, and treatment-resistant depression.

Develop Global’s Pioneer Dome lithium project hits high-grade infill drilling results surpassing resource expectations, setting the stage for a Final Investment Decision next month on an 850,000-tonne DSO operation.

Select Harvests delivered a 33% rise in underlying NPAT despite a wet harvest and higher costs, announcing a fully franked interim dividend and a 10% on-market share buy-back.

Centuria Capital Group is leveraging its $21.8 billion real estate platform to scale AI compute infrastructure through ResetData, aiming to capture growing sovereign and enterprise demand amid global supply constraints.

Advanced Innergy Holdings saw an 84% plunge in half-year profit despite a record £116 million order backlog, driven by project timing and IPO-related costs. The company confirmed full-year guidance and is poised for growth with key acquisitions in aquaculture and subsea manufacturing.

Qoria Limited is moving towards a transformative merger with US-based Aura Consolidated Group, Inc., combining complementary digital safety platforms and targeting growth through a $100 million capital raise and ASX listing.

Australian Vintage Limited has locked in a $128 million refinancing deal extending to 2029 and reported a significant cash flow turnaround in FY26, driven by innovation and strategic acquisitions.

Element 25 has locked in Regroup Australia for long-term mining and ore haulage contracts, streamlining its Butcherbird Expansion Project supply chain and pushing towards a 1.1 Mtpa manganese output.

HighCom Limited has locked in a $4.5 million loan facility with Commonwealth Bank, replacing its US debt and complementing a recent $7.8 million capital raise to fuel working capital and sales expansion.

Cryosite Limited delivered a robust 22% revenue increase and 28% EBITDA growth for the ten months to April 2026, powered by expanding clinical trial activity and infrastructure upgrades.

Endeavour Group unveils a refreshed strategy focusing on price leadership in retail, accelerated hotel portfolio investment, and a $300 million cost reduction program to drive long-term shareholder value.

Nexalis Therapeutics (ASX: NX1) has voluntarily suspended trading of its shares pending a material announcement on its existing debt funding facility, extending a recent trading halt. The suspension is set to last until the earlier of the announcement release or resumption of trading on 28 May 2026.